Remeditex Ventures LLC 3
3 · Menlo Therapeutics, Inc. · Filed Jan 24, 2018
Insider Transaction Report
Form 3
Remeditex Ventures LLC
10% Owner
Holdings
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,650 underlying)Series C Preferred Stock
Exercise: $0.00→ Common Stock (304,576 underlying)- 1,482,854
Common Stock
Series B Preferred Stock
Exercise: $0.00→ Common Stock (871,583 underlying)
Footnotes (3)
- [F1]Each of the 7,150 shares Series A Preferred Stock held by the reporting person is convertible, at any time, at the holder's election, into 0.3707 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert into 0.3707 shares of the Issuer's common stock. The Series A Preferred Stock has no expiration date.
- [F2]Each of the 2,351,097 shares Series B Preferred Stock held by the reporting person is convertible, at any time, at the holder's election, into 0.3707 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert into 0.3707 shares of the Issuer's common stock. The Series B Preferred Stock has no expiration date.
- [F3]Each of the 821,596 shares Series C Preferred Stock held by the reporting person is convertible, at any time, at the holder's election, into 0.3707 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series C Preferred Stock will automatically convert into 0.3707 shares of the Issuer's common stock. The Series C Preferred Stock has no expiration date.